NovaBay Pharmaceuticals Inc. [NBY] has traded in a range of $0.24 to $1.94 in the last 1 year. As of this writing, the stock is at $0.64, up 0.20%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, NBY shares are 0.79% up with the monthly amount drift of 23.08% and seems well in a long time frame.
On 23, November 2020, NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreement. According to news published on Yahoo Finance, NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market, announces the signing of an agreement with Paragon Care Group Australia Pty Ltd for the exclusive distribution of Avenova in Australia. Paragon Care Group will begin distributing Avenova directly to consumers under its Designs For Vision brand beginning in early 2021.
Analyst Birdseye View:
The most recent analyst activity for NovaBay Pharmaceuticals Inc. [AMEX:NBY] stock was on July 06, 2018, when it was Reiterated with a Buy rating from H.C. Wainwright, which also raised its 12-month price target on the stock to $4. Before that, on September 18, 2019, Ladenburg Thalmann Recapitulated a Buy rating and elevated its amount target to $1.10. On November 15, 2017, Laidlaw Reiterated a Buy rating and plunged its price target on this stock from $10 to $8. On June 05, 2017, ROTH Capital Initiated a Buy rating and increased its price target to $5.50. On March 27, 2017, Laidlaw Initiated a Buy rating and increased its price target to $10. On February 06, 2017, Rodman & Renshaw Initiated a Buy rating and boosted its amount on this stock to $6. On March 07, 2016, Maxim Group Downgrade a Hold rating. Maxim Group elevated its amount target by recapitulating a higher weight for this stock.
In the past 52 weeks of trading, this stock has oscillated between a low of $0.24 and a peak of $1.94. Right now, according to Wall Street analyst the average 12-month amount target is $2.63. At the most recent market close, shares of NovaBay Pharmaceuticals Inc. [AMEX:NBY] were valued at $0.64.
NovaBay Pharmaceuticals Inc. [AMEX:NBY] most recently reported quarterly sales of 2.17 billion, which represented growth of 37.50%. This publicly-traded organization’s revenue is $235,679 per employee, while its income is -$345,964 per employee. This company’s Gross Margin is currently 61.50%, its Operating Margin is -70.30%, its Pretax Margin is -146.26, and its Net Margin is -146.79. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -94.14, -326.88, -185.30 and -301.21 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 80.61 and the whole liability to whole assets at 36.06. It shows enduring liability to the whole principal at 10.06 and enduring liability to assets at 0.05 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 0.6251 points at 1st support level, the second support level is making up to 0.6101. But as of 1st resistance point, this stock is sitting at 0.6500 and at 0.6599 for 2nd resistance point.
NovaBay Pharmaceuticals Inc. [NBY] reported its earnings at -$0.08 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.04/share signifying the difference of -0.04 and -100.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.15 calling estimates for -$0.05/share with the difference of -0.1 depicting the surprise of -200.00%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for NovaBay Pharmaceuticals Inc. [AMEX:NBY] is 5.30. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.22. Now if looking for a valuation of this stock’s amount to sales ratio it’s 2.10 and it’s amount to book ratio is 18.38.
The most recent insider trade was by WU MIJIA, Director, and it was the sale of 20000.0 shares on Aug 17. Fu Jian Ping, the 10% Owner, completed a sale of 1.3 million shares on Aug 01.